

PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2019-05-14

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2019

STRONG SALES GROWTH DURING APRIL; ZINZINO BASED REVENUE INCREASED 36% AND THE TOTAL GROUP REVENUE WITH A TOTAL OF 29% COMPARED WITH THE PREVIOUS YEAR.

The revenue for Zinzino's sales markets increased by 36% to SEK 53.4 (39.4) million due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 8% and amounted to SEK 6.1 (6.6) million. Overall, the Group increased revenues by 29 % to SEK 59.5 (46.0) million compared with the previous year.

Accumulated income January - April increased by 24% to SEK 227.7 (183.7) million compared with the previous year.

Revenues distributed as follows:

Regions MSEK	Apr-19	Apr-18	Change	YTD 2019	YTD 2018	Change
Baltic Markets	4.4	3.7	20%	18.0	14.1	27%
Nordic Markets	29.1	29.0	1%	125.7	121.9	3%
Europa Other Markets	17.4	5.3	229%	60.4	19.6	209%
North America	2.1	1.5	46%	7.3	6.3	16%
Australia	0.3	0.0		0.3	0,0	
Zinzino	53.4	39.4	36%	211.7	161.9	31%
Faun Pharma	6.1	6.6	-8%	16.0	21.8	-26%
Zinzino Group	59.5	46.0	29%	227.7	183.7	24%

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information please contact:

Dag Bergheim Pettersen, CEO Zinzino, Mobile: +47 (0) 93 22 57 00
zinzino.com

Pictures for free publication:

Marcus Tollbom, Mobile: +46 (0) 70 190 03 12

Certified Adviser:

Erik Penser Bank Aktiefbolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 10:00 the 14th of May, 2019.

Zinzino AB (publ.) is a direct sales company that operates throughout Europe and North America. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 34 markets across Europe, North America and Australia. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, USA and Australia. Zinzino is a public company and its shares are listed on Nasdaq First North. In 2016, Zinzino was recognized with the award "Superföretag 2015" by Veckans Affärer and the "Gazelle" award by Dagens Industri.